Management of moderately severe graveś orbitopathy

Graves' Orbitopathy: A Multidisciplinary Approach - Questions and Answers

Volumn , Issue , 2010, Pages 120-158

  Kahaly, George J ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 79951692401     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1159/000320435     Document Type: Chapter

References (82)

1. Bartalena L, Baldeschi L, Dickinson A, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits M, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas GE, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM; European Group on Graveś Orbitopathy (EUGOGO): Consensus statement of the European Group on Graveś orbitopathy (EUGOGO) on management of GO. Eur J Endo-crinol 2008;158:273-285.
2. Bartalena L, Baldeschi L, Dickinson AJ, Eckstein A, Kendall-Taylor P, Marcocci C, Mourits MP, Perros P, Boboridis K, Boschi A, Currò N, Daumerie C, Kahaly GJ, Krassas G, Lane CM, Lazarus JH, Marinò M, Nardi M, Neoh C, Orgiazzi J, Pearce S, Pinchera A, Pitz S, Salvi M, Sivelli P, Stahl M, von Arx G, Wiersinga WM: Consensus statement of the European group on Graveś orbitopathy (EUGOGO) on management of Graveś orbitopathy. Thyroid 2008;18:333-346.
3. Bahn R: The EUGOGO consensus statement on the management of Graveś orbitopathy: equally applicable to North American clinicians and patients. Thyroid 2008;18:281-282.
4. Bartalena L, Tanda ML: Clinical practice. Graveś ophthalmopathy. N Engl J Med 2009;360:994-1001.
5. Bahn RS: Graveś ophthalmopathy. N Engl J Med 2010;362:726-738.
6. Stemberger K, Kahaly GJ, Pitz S: Update on thyroid eye disease. Compr Ophthalmol Update 2006;7:287-298.
7. Terwee CB, Prummel MF, Gerding MN, Kahaly GJ, Dekker FW, Wiersinga WM: Measuring disease activity to predict therapeutic outcome in Graveś ophthalmopathy. Clin Endocrinol 2005;62:145-155.
8. Kahaly GJ: Imaging in thyroid-associated orbitopathy. Eur J Endocrinol 2001;145:107-118.
9. Kahaly GJ: Recent developments in Graveś ophthalmology imaging. J Endocrinol Invest 2004;27: 254-258.
10. Kahaly GJ, Bang H, Berg W, Dittmar M: Alphafodrin as a putative autoantigen in Graveś ophthalmopathy. Clin Exp Immunol 2005;140:166-172.
11. Abalkhail S, Doi SAR, Al-Shoumer KAS: The use of corticosteroids versus other treatments for Graveś ophthalmopathy: a quantitative evaluation. Med Sci Monitor 2003;9:CR477-CR483.
12. Bartalena L, Marcocci C, Bogazzi F, Panicucci M, Lepri A, Pinchera A: Use of corticosteroids to prevent progression of Graveś ophthalmopathy after radioiodine therapy for hyperthyroidism. N Engl J Med 1989;321:1349-1352.
13. Kahaly GJ, Petrak F, Hardt J, Pitz S, Egle UT: Psychosocial morbidity of Graveś orbitopathy. Clin Endocrinol 2005;63:395-402.
14. Tehrani M, Krummenauer F, Mann WJ, Pitz S, Dick HB, Kahaly GJ: Disease-specific assessment of quality of life after decompression surgery for Graveś ophthalmopathy. Eur J Ophthalmol 2004;14:193-199.
15. Marcocci C, Bartalena L, Panicucci M, Marconcini C, Cartei F, Cavallacci G, Laddaga M, Campobasso G, Baschieri L, Pinchera A: Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graveś ophthalmopathy: a comparative study. Clin Endocrinol 1987;27:33-42.
16. Prummel MF, Mourits MP, Blank L, Berghout A, Koornneef L, Wiersinga WM: Randomized double-blind trial of prednisone versus radiotherapy in Graveś ophthalmopathy. Lancet 1993;342:949-954.
17. Bartalena L, Marcocci C, Tanda ML, Manetti L, Dell'Unto E, Bartolomei MP, Nardi M, Martino E, Pinchera A: Cigarette smoking and treatment out-comes in Graveś ophthalmopathy. Ann Intern Med 1998;129:632-635.
18. Ponto KA, Kahaly GJ: Current management of endocrine orbitopathy. Med Klin (Munich) 2008; 103:717-730.
19. Kubota S, Ohye H, Nishihara E, Kudo T, Ito M, Fukata S, Amino N, Kuma K, Miyauchi A: Effect of high dose methylprednisolone pulse therapy followed by oral prednisolone administration on the production of anti-TSH receptor antibodies and clinical outcome in Graveś disease. Endocr J 2005; 52:735-741.
20. Kahaly GJ, Pitz S, Hommel G, Dittmar M: Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graveś orbitopathy. J Clin Endocrinol Metab 2005;90:5234-5240.
21. Aktaran S, Akarsu E, Erbagci I, Araz M, Okumus S, Kartal M: Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graveś ophthalmopathy. Int J Clin Pract 2007;61:45-51.
22. van Geest RJ, Sasim IV, Koppeschaar HP, Kalmann R, Stravers SN, Bijlsma WR, Mourits MP: Methylprednisolone pulse therapy for patients with moderately severe Graveś orbitopathy: a prospective, randomized, placebo-controlled study. Eur J Endocrinol 2008;158:229-237.
23. Macchia PE, Bagattini M, Lupoli G, Vitale M, Vitale G, Fenzi G: Highdose intravenous corticosteroid therapy for Graveś ophthalmopathy. J Endocrinol Invest 2001;24:152-158.
24. Kauppinen-Mäkelin R, Karma A, Leinonen E, Löyttyniemi E, Salonen O, Sane T, Setälä K, Viikari J, Heufelder A, Välimäki M: High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy. Acta Ophthalm Scan 2002;80:316-321.
25. Menconi F, Marinò M, Pinchera A, Rocchi R, Mazzi B, Nardi M, Bartalena L, Marcocci C: Effects of total thyroid ablation versus neartotal thyroidectomy alone on mild to moderate Graveś orbitopathy treated with intravenous glucocorticoids. J Clin Endocrinol Metab 2007;92:1653-1658.
26. Gursoy A, Cesur M, Erdogan MF, Corapcioglu D, Kamel N: New-onset acute heart failure after intravenous glucocorticoid pulse therapy in a patient with Graveś ophthalmopathy. Endocrine 2006;29: 513-516.
27. Owecki M, Sowinski J: Acute myocardial infarction during high-dose methylprednisolone therapy for Graveś ophthalmopathy. Pharm World Sci 2006;28: 73-75.
28. Lendorf ME, Rasmussen AK, Fledelius HC, Feldt-Rasmussen U: Cardiovascular and cerebrovascular events in temporal relationship to intravenous glucocorticoid pulse therapy in patients with severe endocrine ophthalmopathy. Thyroid 2009;19:1431-1432.
29. Weissel M, Hauff W: Fatal liver failure after high-dose glucocorticoid pulse therapy in a patient with severe thyroid disease. Thyroid 2000;10:521.
30. Marino M, Morabito E, Brunetto MR, Bartalena L, Pinchera A, Marcocci C: Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graveś ophthalmopathy. Thyroid 2004;14:403-406.
31. Salvi M, Vannuchi G, Sbrozzi P, Bottari del Castello A, Carnevali A, Fargion S, Beck-Peccoz P: Onset of autoimmune hepatitis during intravenous steroid therapy for thyroid-associted ophthalmopathy in a patient with hashimoto' s thyroiditis: case report. Thyroid 2004;14:631-634.
32. Sánchez-Ortiga R, Moreno-Pérez O, González Sánchez V, Arias Mendoza N, Mauri Dot M, Alfayate Guerra R, López Macia A, Picó Alfonso A: Treatment of Graveś ophthalmopathy with high-dose intravenous methylprednisolone: a comparison of two dosing regimens. Endocrinol Nutr. 2009; 56:118-122.
33. Le Moli R, Baldeschi L, Saeed P, Regensburg N, Mourits MP, Wiersinga WM: Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graveś opthalmopathy. Thyroid 2007;17:357-362.
34. Bordaberry M, Marques DL, Pereira-Lima JC, Marcon IM, Schmid H: Repeated peribulbar injections of triamcinolone acetonide: a successful and safe treatment for moderate to severe Graveś ophthalmopathy. Acta Ophthalmol 2009;87:58-64.
35. Chee E, Chee SP: Subconjunctival injection of triamcinolone in the treatment of lid retraction of patients with thyroid eye disease: a case series. Eye (Lond) 2008;22:311-315.
36. Ebner R, Devoto MH, Weil D, Bordaberry M, Mir C, Martinez H, Bonelli L, Niepomniszcze H: Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol 2004;88:1380-1386.
37. Kahaly GJ, Roesler HP, Kutzner J, Pitz S, Müller-Forell W, Beyer J, Mann J: Radiotherapy for thyroid-associated orbitopathy. Exp Clin Endocrinol Diab 1999;107:201-207.
38. Kahaly GJ, Gorman CA, Kal HB, Mourits MP, Pinchera A, Tan S, Prummel MF: Radiotherapy for Graveś ophthalmopathy; in Prummel MF (ed): Recent developments in Graveś ophthalmopathy. Kluwer Academic Publishers, 2000, Boston, pp 115-131.
39. Mourits MP, van Kempen-Harteveld ML, Garcia MB, Koppeschaar HP, Tick L, Terwee CB: Radiotherapy for Graveś orbitopathy: randomised placebo-controlled study. Lancet 2000;355:1505-1509.
40. Prummel MF, Terwee CB, Gerding MN, Baldeschi L, Mourits MP, Blank L, Dekker FW, Wiersinga WM: A randomized controlled trial of orbital radio-therapy versus sham irradiation in patients with mild Graveś ophthalmopathy. J Clin Endocrinol Metab 2004;89:15-20.
41. Gorman CA, Garrity JA, Fatourechi V, Bahn RS, Petersen IA, Stafford SL, Earle JD, Forbes GS, Kline RW, Bergstralh EJ, Offord KP, Rademacher DM, Stanley NM, Bartley GB: A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graveś ophthalmopathy. Ophthalmology 2001;108:1523-1534.
42. Kahaly GJ, Rösler HP, Pitz S, Krummenauer F, Hommel G: Radiotherapy for Graveś ophthalmop-athy. J Clin Endocrinol Metab 2001;86:2327-2328.
43. Kahaly GJ, Rosler HP, Pitz S, Hommel G: Low versus high-dose radiotherapy for Graveś ophthalmopathy: a randomized, single blind trial. J Clin Endocrinol Metab 2000;85:102-108.
44. Robertson DM, Buettner H, Gorman CA, Garrity JA, Fatourechi V, Bahn RS, Petersen IA, Stafford SL, Earle JD, Forbes GS, Kline RW, Bergstralh EJ, Offord KP, Rademacher DM, Stanley NM, Bartley GB: Retinal microvascular abnormalities in patients treated with external radiation for graves ophthalmopathy. Arch Ophthalmol 2003;121:652-657.
45. Wakelkamp IMMJ, Tan H, Saeed P, Schlingenmann RO, Verbraak FD, Blank LECM, Prummel MF, Wiersinga WM: Orbital irradiation for Graveś ophthalmopathy. Is it safe? A longterm followup study. Ophthalmology 2004;111:1557-1562.
46. Marcocci C, Bartalena L, Rocchi R, Marino M, Menconi F, Morabito E, Mazzi B, Mazzeo S, Sartini MS, Nardi M, Cartei F, Cionini L, Pinchera A: Longterm safety of orbital radiotherapy for Graveś ophthalmopathy. J Clin Endocrinol Metab 2003;88: 3561-3566.
47. Bartalena L, Marcocci C, Chiovato L, Laddaga M, Lepri G, Andreani D, Cavallacci G, Baschieri L, Pinchera A: Orbital cobalt irradiation combined with systemic corticosteroids for Graveś ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 1983;56:1139-1144.
48. Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Lepri A, Pinchera A: Orbital radiotherapy combined with high dose systemic glucocorticoids for Graveś ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study. J Endocrinol Invest 1991;14:853-860.
49. Marcocci C, Bartalena L, Tanda ML, Manetti L, Dell'Unto E, Rocchi R, Barbesino G, Mazzi B, Bartolomei MP, Lepri P, Cartei F, Nardi M, Pinchera A: Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graveś ophthalmopathy: results of a pro-spective, single-blind, randomized study. J Clin Endocrinol Metab 2001;86:3562-3567.
50. Ng CM, Yuen HKL, Choi KL, Chan MK, Yuen KT, Ng YW, Tiu SC: Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderatetosevere Graveś ophthalmopathy: a preliminary study. Hong Kong Med J 2005;11:322-330.
51. Ohtsuka K, Sato A, Kawaguchi S, Hashimoto M, Suzuki Y: Effect of steroid pulse therapy with and without orbital radiotherapy on Graveś ophthalmopathy. Am J Ophthalmol 2003;135:285-290.
52. Kahaly GJ, Schrezenmeir J, Krause U, Schweikert B, Meuer S, Muller W, Dennebaum R, Beyer J: Ciclosporin and prednisone vs. prednisone in treatment of Graveś ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest 1986;16:415-422.
53. Kahaly GJ, Schrezenmeir J, Schweikert B, Müller W, Krause U, Beyer J: Remissionmaintaining effect of cyclosporine in endocrine ophthalmopathy. Transplant Proc 1986;18:844-846.
54. Kahaly GJ, Yuan JP, Krause U, Hülbusch K, Beyer J: Ciclosporin and thyroidstimulating immunoglobulins in endocrine orbitopathy. Res Exp Med 1989;189:355-362.
55. Kahaly GJ, Moncayo R, Bemetz U, Krause U, Beyer J, Pfeifer EF: Eye muscle antibodies in endocrine exophthalmos. Horm Metab Res 1989;12:137-141.
56. Prummel MF, Mourits MP, Berghout A, Krenning EP, van der Gaag R, Koornneef L, Wiersinga WM: Prednisone and cyclosporine in the treatment of severe Graveś ophthalmopathy. N Engl J Med 1989; 321:1353-1359.
57. Kazatschkine MD, Kaveri SV: Advances in immunology: immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-755.
58. Kahaly GJ, Pitz S, Muller-Forell W, Hommel G: Randomized trial of intravenous immunoglobulins versus prednisolone in Graveś ophthalmopathy. Clin Exp Immunol 1996;106:197-202.
59. Antonelli A, Saracino A, Alberti B, Canapicchi R, Cartei F, Lepri A, Laddaga M, Baschieri L: High-dose intravenous immunoglobulin treatment in Graveś ophthalmopathy. Acta Endocrinol 1992;126:13-23.
60. Baschieri L, Antonelli A, Nardi S, Alberti B, Lepri A, Canapicchi R, Fallahi P: Intravenous immunoglobulin versus corticosteroid in treatment of Graveś ophthalmopathy. Thyroid 1997;7:579-585.
61. Perros P, Weightman DR, Crombie AL, Kendall-Taylor P: Azathioprine in the treatment of thyroid-associated ophthalmopathy. Acta Endocrinol 1990; 122:8-12.
62. Kahaly GJ, Lieb W, Müller-Forell W, Mainberger M, Beyer J, Vollmer J, Staiger C: Ciamexone in endocrine orbitopathy. Acta Endocrinol 1990;122:13-21.
63. Paridaens D, van den Bosch WA, van der Loos TL, Krenning EP, van Hagen PM: The effect of etanercept on Graveś ophthalmopathy: a pilot study. Eye (Lond) 2005;19:1286-1289.
64. El Fassi D, Nielsen CH, Hasselbalch HC, Hegedüs L: The rationale for B lymphocyte depletion in Graveś disease. Monoclonal antiCD20 antibody therapy as a novel treatment option. Eur J Endocrinol 2006;154: 623-632.
65. El Fassi D, Nielsen CH, Bonnema SJ, Hasselbalch HC, Hegedüs L: B lymphocyte depletion with the monoclonal antibody rituximab in Graveś disease: a controlled pilot study. J Clin Endocrinol Metab 2007;92:1769-1772.
66. El Fassi D, Nielsen CH, Hasselbalch HC, Hegedüs L: Treatment-resistant severe, active Graveś ophthalmopathy successfully treated with B lymphocyte depletion. Thyroid 2006;16:709-710.
67. Salvi M, Vannucchi G, Campi I, Rossi S, Bonara P, Sbrozzi F, Guastella C, Avignone S, Pirola G, Ratiglia R, Beck-Peccoz P: Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression. Eur J Endocrinol 2006;154:511-517.
68. Salvi M, Vannucchi G, Campi I, Currò N, Simonetta S, Covelli D, Pignataro L, Guastella C, Rossi S, Bonara P, Dazzi D, Ratiglia R, Beck-Peccoz P: Rituximab treatment in a patient with severe thyroid-associated ophthalmopathy: effects on orbital lymphocytic infiltrates. Clin Immunol 2009;131:360-365.
69. Nielsen JF, El Fassi D, Nielsen CH, Hegedüs L, Lauer SA, Silkiss RZ, Prause JU: Evidence of orbital B and T cell depletion after rituximab therapy in Graveś ophthalmopathy. Acta Ophthalmol 2009;87:927-929.
70. Salvi M, Vannucchi G, Campi I, Currò N, Dazzi D, Simonetta S, Bonara P, Rossi S, Sina C, Guastella C, Ratiglia R, Beck-Peccoz P: Treatment of Graveś disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study. Eur J Endocrinol 2007;156:33-40.
71. Khanna D, Chong KK, Afifiyan NF, Hwang CJ, Lee DK, Garneau HC, Goldberg RA, Darwin CH, Smith TJ, Douglas RS: Rituximab treatment of patients with severe, corticosteroid-resistant thyroid-associated ophthalmopathy. Ophthalmology 2010;117: 133-139.
72. Kung AW, Michon J, Tai KS, Chan FL: The effect of somatostatin versus corticosteroid in the treatment of Graveś ophthalmopathy. Thyroid 1996;6:381-384.
73. Dickinson AJ, Vaidya B, Miller M, Coulthard A, Perros P, Baister E, Andrews CD, Hesse L, Heverhagen JT, Heufelder AE, Kendall-Taylor P: Double-blind, placebo-controlled trial of octreotide longacting repeatable (LAR) in thyroidassociated ophthalmopathy. J Clin Endocrinol Metab 2004;89:5910-5915.
74. Wemeau JL, Caron P, Beckers A, Rohmer V, Orgiazzi J, Borson-Chazot F, Nocaudie M, Perimenis P, Bisot-Locard S, Bourdeix I, Dejager S: Octreotide (long-acting release formulation) treatment in patients with Graveś orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab 2005;90:841-848.
75. Chang TC, Liao SL: Slow-release Lanreotide in Graveś opthalmopathy: a double-blind randomized, placebo-controlled clinical trial. J Endocrinol Invest 2006;29:413-422.
76. Stan MN, Garrity JA, Bradley EA, Woog JJ, Bahn MM, Brennan M, Bryant SC, Achenbach SJ, Bahn RS: Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graveś ophthalmopathy. J Clin Endocrinol Metab 2006;91:4817-4824.
77. Feldman-Billard S, Lissak B, Benrabah R, Kassaei R, Héron E: Intravenous pulse methylprednisolone therapy in eye disease: effect on glucose tolerance. Ophthalmology 2003;110:2369-2371.
78. Feldman-Billard S, Lissak B, Kassaei R, Benrabah R, Héron E: Short-term tolerance of pulse methylpred-nisolone therapy in patients with diabetes mellitus. Ophthalmology 2005;112:511-515.
79. Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, Ezrachi D, Shimon I, Leibovici L: Treatment modal-ities for Graveś ophthalmopathy: systematic review and metaanalysis. J Clin Endocrinol Metab 2009;94: 2708-2716.
80. Ponto KA, Pitz S, Mann WJ, Weber MM, Pfeiffer N, Kahaly GJ: Management of Graveś orbitopathy: evidence-based recommendations. Dtsch Med Wochenschr 2009;134:2521-2524.
81. Bradley EA, Gower EW, Bradley DJ, Meyer DR, Cahill KV, Custer PL, Holck DE, Woog JJ: Orbital radiation for Graveś ophthalmopathy: a report by the American Academy of Ophthalmology. Ophthalmology 2008;115:398-409.
82. Zoumalan CI, Cockerham KP, Turbin RE, Volpe NJ, Kazim M, Douglas RS, Feldon SE: Efficacy of corti-costeroids and external beam radiation in the management of moderate to severe thyroid eye disease. J Neuroophthalmol 2007;27:205-214.